Literature DB >> 17701113

[Health in older age: cost of illness and cost-effectiveness of prevention].

I Brandes1, U Walter.   

Abstract

The objective of prevention is to avoid or to delay health impairments and diseases. For older people it is important to maintain their independence and to avoid and reduce the need for external help such as nursing care. Good starting points are the strategies for healthy life-style. Physical activity, smoking abstinence, and normal weight have proven to have their positive medical and economic effect on many chronic diseases such as type 2 diabetes mellitus, cardiovascular diseases, and certain types of dementia. The potential of prevention increases as those diseases affect one another. As for other health care, the cost-effectiveness of preventive measures must also be examined. There are few German studies addressing the cost-benefit of the non-medication prevention. Results from international studies can only partly be transferred to the German context. The cost-effectiveness for prevention for elderly people has been very rarely researched. Research in the field of prevention is so far not very well developed as for other health fields. There is a need for more specific research for methods, interventions and target groups. In health economics major challenges arise from different time schedules and various purchasers, as well as from the evaluation of human capital for elderly.

Entities:  

Mesh:

Year:  2007        PMID: 17701113     DOI: 10.1007/s00391-007-0471-1

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  24 in total

Review 1.  [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].

Authors:  J Wasem; F Hessel; C Kerim-Sade
Journal:  Psychiatr Prax       Date:  2001-07

Review 2.  [Cost-effectiveness of coronary heart disease prevention].

Authors:  G Wendland; G Klever-Deichert; K Lauterbach
Journal:  Z Kardiol       Date:  2002

3.  [Primary prevention and health promotion--health science fundamentals for health policy].

Authors:  R Rosenbrock
Journal:  Gesundheitswesen       Date:  2004-03

4.  [Prevention of disability in the elderly].

Authors:  H P Thomas; E Steinhagen-Thiessen
Journal:  Internist (Berl)       Date:  2004-02       Impact factor: 0.743

5.  Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Authors:  James Ryan; York Zoellner; Birgit Gradl; Bram Palache; Jeroen Medema
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

Review 6.  [Economic evaluation within the scope of clinical studies].

Authors:  R Walshe; V Diehl
Journal:  Internist (Berl)       Date:  1998-09       Impact factor: 0.743

7.  [Injury prevention in the elderly population].

Authors:  M Richter; C Becker; J Seifert; F Gebhard; O Pieske; M Holch; G Lob
Journal:  Unfallchirurg       Date:  2002-12       Impact factor: 1.000

8.  [Cost-effectiveness of prevention of coronary disease in Germany].

Authors:  K W Lauterbach; A Gerber; G Klever-Deichert; B Stollenwerk
Journal:  Z Kardiol       Date:  2005

Review 9.  [Dementia in advanced age: estimating incidence and health care costs].

Authors:  H Bickel
Journal:  Z Gerontol Geriatr       Date:  2001-04       Impact factor: 1.281

Review 10.  [Prophylactic influenza vaccination: what is the situation in Germany?].

Authors:  P Wutzler
Journal:  Dtsch Med Wochenschr       Date:  2006-03-03       Impact factor: 0.628

View more
  2 in total

1.  [Fall and fracture prevention based on the National Expert Standard. Implementation and costs in a real world setting in nursing homes].

Authors:  S Heinrich; I Weigelt; K Rapp; C Becker; U Rissmann; H-H König
Journal:  Z Gerontol Geriatr       Date:  2012-02       Impact factor: 1.281

Review 2.  [Skin health promotion in the elderly].

Authors:  J Kottner; A Lichterfeld; U Blume-Peytavi; A Kuhlmey
Journal:  Z Gerontol Geriatr       Date:  2015-04       Impact factor: 1.281

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.